PhaseV develops advanced AI/ML solutions to optimize clinical development and execution. Biopharma and CROs leverage PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions. PhaseV's platform has reduced trial costs by 50%, decreased enrollment size and trial duration by 40%, and increased the probability of trial success by over 30%. The company has delivered results for more than 40 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others.